GlobeNewsWire
18 Feb 2026, 18:04 UTC · 30w ago
Verdict
Headline takes no side. We score OCUL −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Ocular Therapeutix (OCUL) saw its stock price decline approximately 27% following the release of SOL-1 Phase 3 trial topline results.
More negative than 99% of claims this week
Ocular Therapeutix announced SOL-1 Phase 3 trial results showing 74% of patients maintained vision at nine months and 66% at twelve months.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Law firm Johnson Fistel is investigating Ocular Therapeutix for potential violations of federal securities laws related to investor losses.
More negative than 78% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a legal investigation by a law firm following a 27% stock price drop after trial results.
More negative than 86% of ticker scores this week
The company is being investigated by a law firm on behalf of investors who suffered losses.
More negative than 86% of ticker scores this week
The company is being investigated by a law firm on behalf of investors who suffered losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
5h ago
+50.2%
Price is moving against the score
$10.50 vs $6.99 close before publication (Feb 17) · not market-adjusted
OCUL chart →
